A Randomized, Double‐Blind, Placebo‐Controlled, Phase II Study of Regorafenib Versus Placebo in Advanced/Metastatic, Treatment‐Refractory Liposarcoma: Results from the SARC024 Study

LESSONS LEARNED: The results from the liposarcoma cohort of SARC024 confirm previously published data and do not support the routine use of regorafenib in this patient population. Continued exploration of novel therapies, including combination approaches, is warranted for a patient population in who...

Descripción completa

Detalles Bibliográficos
Autores principales: Riedel, Richard F., Ballman, Karla V., Lu, Yao, Attia, Steven, Loggers, Elizabeth T., Ganjoo, Kristen N., Livingston, Michael B., Chow, Warren, Wright, Jennifer, Ward, John H., Rushing, Daniel, Okuno, Scott H., Reed, Damon R., Liebner, David A., Keedy, Vicki L., Mascarenhas, Leo, Davis, Lara E., Ryan, Christopher, Reinke, Denise K., Maki, Robert G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Clinical Trial Results
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7648334/
https://www.ncbi.nlm.nih.gov/pubmed/32701199
http://dx.doi.org/10.1634/theoncologist.2020-0679

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7648334/
https://www.ncbi.nlm.nih.gov/pubmed/32701199
http://dx.doi.org/10.1634/theoncologist.2020-0679

Ejemplares similares